RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target
Bio-Techne Corporation
Bio-Techne Corporation TECH | 0.00 |
RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:
TECH) with a Outperform and announces $62 price target.
